CITY OF INDUSTRY, Calif., Oct. 27 /PRNewswire-FirstCall/ -- U.S. BioDefense, Inc. announced today that its Option Agreement to license United States Patent Application No. 6,485,722 B1 entitled “Method for Selective Engraftment of Drug-Resistant Hematopoietic Stem Cells” and related applications was unilaterally terminated by University of Minnesota.
U.S. BioDefense, Inc. management will continue to pursue full license agreements for commercializing innovative new technologies. The company recently announced a milestone collaboration agreement with AntiCancer, to research, develop and commercialize novel approaches on utilizing human neural crest stem cells and their potentials in human transplantation.
Safe Harbor Statement Forward-Looking Statements Included in this release are certain “forward-looking” statements, involving risks and uncertainties, which are covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding U.S. BioDefense’s financial performance. Such statements are based on management’s current expectations and are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those referred to or implied by such statements. In addition, actual future results may differ materially from those anticipated, depending on a variety of factors, including continued maintenance of favorable license arrangements, success of market research identifying new product opportunities, successful introduction of new products, continued product innovation, the success of enhancements to U.S. BioDefense’s brand image, sales and earnings growth, ability to attract and retain key personnel, and general economic conditions affecting consumer spending, including uncertainties relating to global political conditions, such as terrorism. Information with respect to important factors that should be considered is contained in U.S. BioDefense’s Annual Report on Form 10-K as filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. U.S. BioDefense does not intend to update any of the forward-looking statements after the date of this release to conform these statements to actual results or to changes in its expectations, except as may be required by law.
U.S. BioDefense, Inc. David Chin 626-961-0562 info@usbiodefense.com
U.S. BioDefense, Inc.
CONTACT: David Chin of U.S. BioDefense, Inc., +1-626-961-0562,info@usbiodefense.com
